Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | SD-101 plus pembrolizumab for HNSCC

Ezra Cohen • 19 Oct 2018
ESMO 2018
Head and Neck Cancer Pembrolizumab SD-101

Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses an exciting trial of SD-101, a TLR9 agonist that is given via intratumor injection, with pembrolizumab for head and neck squamous cell carcinoma (NCT02521870). The study investigated this combination in two groups: patients who had never received a PD-1 inhibitor before, and PD-1 refractory patients. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Ezra Cohen

PD-L1 and alternative biomarkers in head and neck cancer
3:13
PD-L1 and alternative biomarkers in head and neck cancer
Ezra Cohen • 16 Apr 2023
The future of liquid biopsies in head and neck cancer
1:41
The future of liquid biopsies in head and neck cancer
Ezra Cohen • 16 Apr 2023
Petosemtamab has promising activity in advanced HNSCC
2:01
Petosemtamab has promising activity in advanced HNSCC
Ezra Cohen • 16 Apr 2023
Mono or combination immunotherapy for HNSCC?
1:37
Mono or combination immunotherapy for HNSCC?
Ezra Cohen • 26 Oct 2018

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals